Lopinavir protein binding in HIV-1-infected pregnant women

HIV Medicine

Volumn 11, Issue 4, 2010, Pages 232-238

  Aweeka, F T ^a   Stek, A ^b   Best, B M ^c   Hu, C ^d   Holland, D ^c   Hermes, A ^e   Burchett, S K ^f   Read, J ^g   Mirochnick, M ^h   Capparelli, E V ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ABBOTT LABORATORIES   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lopinavir; Pharmacokinetics; Plasma proteins; Pregnancy; Protein binding

Indexed keywords

ALBUMIN; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OROSOMUCOID;

ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; THIRD TRIMESTER PREGNANCY;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; PROTEIN BINDING; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 77950825016     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00767.x     Document Type: Article

References (16)

1. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf, USPHS Task Force Recommendations for the use of antiretroviral drugs in HIV-infected pregnant women for maternal health and interventions to reduce perinatal HIV transmission in the US. Available at, (accessed 29 April 2009)
2. Tracy TS, Venkataramanan R, Glover DD. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 2005, 192:633-639.
3. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980, 10:301-328.
4. Stek AM, Mirochnick M, Capparelli E. Reduced lopinavir exposure during pregnancy. AIDS 2006, 20:1931-1939.
5. Mirochnick M, Best BM, Stek AM. Lopinavir exposure with an increased dose during pregnancy. JAIDS 2008, 49:485-491.
6. Kiser J, Mawhinney S, Kinzie K. Total and unbound lopinavir/ritonavir pharmacokinetics in a concentration-guided study of HIV-infected women throughout pregnancy and post-partum. Montreal, Canada, February 2009 [Poster μ946]
7. Aweeka FT, Rosenkranz SL, Segal Y. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 2006, 20:1833-1841. NIAID AIDS Clinical Trials Group
8. McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006, 7:142-153.
9. Summerfield SG, Stevens AJ, Cutler L. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 2006, 316:1282-1290.
10. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984, 34:395-397.
11. Haram K, Augensen K, Elsayed S. Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. Br J Obstet Gynaecol 1983, 90:139-145.
12. Wood M, Wood AJ. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981, 29:522-526.
13. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990, 18:20-36.
14. Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982, 7:336-352.
15. Motoya T, Thevanayagam LN, Blaschke TF. Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. HIV Med 2006, 7:122-128.
16. Gulati A, Boudinot D, Gerk PM. Binding of lopinavir to human {alpha}1-acid glycoprotein and serum albumin. Drug Metab Dispos 2009, 37:1572-1575.